-+ 0.00%
-+ 0.00%
-+ 0.00%

REVOLUTION MEDICINES ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR RASONQUE™ (DARAXONRASIB) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST LINE METASTATIC PANCREATIC CANCER

Reuters·09/14/2026 20:05:00

Please log in to view news